Contributions
Abstract: PB2217
Type: Publication Only
Background
Aims
To study the effect of tripeptides Pro-Arg-Gly and Gly-Arg-Pro, containing arginine in the molecule, on platelet aggregation and tissue plasminogen activator (t-PA) activity in a healthy organism and the development of the experimental MS.
Methods
Experiments were carried out on Wistar rats weighing 300-350 g in accordance with the ethical principles of the Helsinki Declaration. Two groups of animals were used: healthy rats and rats with experimental MS. Peptides were intranasal injected in doses of 1 mg / kg once daily for 5 days. 0.85% NaCl solution was injected to control rats in the same time frame. MS in rats was caused by a hyper-cholesterol fat-rich diet (FD) for 6 weeks. Blood samples were taken from the jugular vein 1 hour after the last drug administration. Activity of t-PA (fibrin plate method) and ADP-induced platelet aggregation (standard method) were measured in blood plasma.
Results
The intranasal administration of peptides Gly-Arg-Pro, and Pro-Arg-Gly to healthy animals resulted a reduction of platelet aggregation by 23% and 52% compared with the control. Both peptides induced enhancement t-PA activity of 2 or 3.5 times respectively. In rats with experimental MS these effects were preserved, besides, platelet aggregation was decreased by 27% (Pro-Arg-Gly) and 38% (Gly-Arg-Pro) compared with the control.
Conclusion
We concluded that intranasal administration of tripeptides Pro-Arg-Gly and Gly-Arg-Pro to organism of healthy rats and in rats with experimental MS show antiplatelet and fibrinolytic effects of the blood. Thus, arginine-containing peptides could potentially be used as antithrombotic drugs that protect the organism from the blood coagulation and thrombus formation.
Session topic: 34. Thrombosis and vascular biology
Keyword(s): Thrombosis, Plasminogen, Fibrinolysis, Anticoagulants
Abstract: PB2217
Type: Publication Only
Background
Aims
To study the effect of tripeptides Pro-Arg-Gly and Gly-Arg-Pro, containing arginine in the molecule, on platelet aggregation and tissue plasminogen activator (t-PA) activity in a healthy organism and the development of the experimental MS.
Methods
Experiments were carried out on Wistar rats weighing 300-350 g in accordance with the ethical principles of the Helsinki Declaration. Two groups of animals were used: healthy rats and rats with experimental MS. Peptides were intranasal injected in doses of 1 mg / kg once daily for 5 days. 0.85% NaCl solution was injected to control rats in the same time frame. MS in rats was caused by a hyper-cholesterol fat-rich diet (FD) for 6 weeks. Blood samples were taken from the jugular vein 1 hour after the last drug administration. Activity of t-PA (fibrin plate method) and ADP-induced platelet aggregation (standard method) were measured in blood plasma.
Results
The intranasal administration of peptides Gly-Arg-Pro, and Pro-Arg-Gly to healthy animals resulted a reduction of platelet aggregation by 23% and 52% compared with the control. Both peptides induced enhancement t-PA activity of 2 or 3.5 times respectively. In rats with experimental MS these effects were preserved, besides, platelet aggregation was decreased by 27% (Pro-Arg-Gly) and 38% (Gly-Arg-Pro) compared with the control.
Conclusion
We concluded that intranasal administration of tripeptides Pro-Arg-Gly and Gly-Arg-Pro to organism of healthy rats and in rats with experimental MS show antiplatelet and fibrinolytic effects of the blood. Thus, arginine-containing peptides could potentially be used as antithrombotic drugs that protect the organism from the blood coagulation and thrombus formation.
Session topic: 34. Thrombosis and vascular biology
Keyword(s): Thrombosis, Plasminogen, Fibrinolysis, Anticoagulants